Thomas J. Slaga – författare
Visar alla böcker från författaren Thomas J. Slaga. Handla med fri frakt och snabb leverans.
3 produkter
3 produkter
Detox Revolution
A Powerful New Program for Boosting Your Body’s Ability to Fight Cancer and Other Diseases
Häftad, Engelska, 2004
216 kr
Skickas inom 5-8 vardagar
'Dr. Slaga, an eminent environmental health scientist, provides 'state-of-the-science' recommendations on disease prevention and health promotion through good nutrition' - Kenneth Olden, Ph.D., Director, National Institute of Environmental Health Sciences. Which foods really enhance your body's ability to cleanse itself of toxins? Which supplements work in conjunction with superfoods to supercharge your body's ability to fight disease? What lifestyle changes can add years to your life?Find out how to rid your body of life-threatening contaminants through the breakthrough program found in "The Detox Revolution". Throughout this powerful program, you'll discover: ways to avoid exposure to common, harmful substances; the important impact that diet has on supporting your body's ability to fight disease through detoxification; recommendations for nutrition supplements, including what kinds, how much to take, and the best times to take them; an in-depth look at cancer ...and how to avoid it; the detoxifying powers of superfoods ...including chocolate and coffee; and, dozens of easy and delicious recipes that incorporate these beneficial superfoods [author photo].Thomas J.Slaga, Ph.D., is scientific director of the AMC Cancer Research Center and deputy director of the University of Colorado Comprehensive Cancer Research Center as well as chair of the Center for Cancer Causation and Prevention.He is editor-in-chief of the medical journal Molecular Carcinogenesis and consults regularly for the Food and Drug Administration, the Environmental Protection Agency, and the National Cancer Institute. His groundbreaking research on flavonoids and cancer prevention has earned him an international reputation for research excellence. Robin Keuneke is an award-winning health writer and the author of Total Breast Health.
1 637 kr
Skickas inom 10-15 vardagar
Prostaglandins, Leukotrienes, and Cancer is a multi-volume series that will focus on an emerging area of cancer research. In 1968, R.H. Williams first reported that elevated prostaglandin levels are present in human medullary car- cinoma. Since that time, the concept that arachidonic acid metabolites may be in- volved in cancer has expanded to include every aspect of the disease from cell transformation through metastasis. Prostaglandins and leukotrienes are generic terms used to describe a family of bioactive lipids produced from unsaturated fatty acids (principally from and lipoxygenase pathways, respec- arachidonic acid) via the cyclooxygenase tively. Cyclooxygenase products consist of diverse products such as prosta- glandin E2 (POE), prostacyclin (POI) and thromboxane A2 (TXA), whereas 2 2 2 lipoxygenase products consist of hydroperoxy fatty acids and mono-, di- and tri-hydroxy acids including leukotrienes. The precursor fatty acids for the cyclooxygenase and lipoxygenase pathways are present in cellular phospholipids. This finding established an important control point in their biosynthesis-the release of substrate.This occurs in response to numerous stimuli that act at the cell surface. Dr. Bengt Samuelsson's extensive study of the metabolism of pros- taglandins indicated that they are rapidly inactivated on a single pass through pulmonary circulation. Thus, they cannot act as circulating hormones and appear to be made on demand in or in the vicinity of target tissues leading to the concept that prostaglandins are local hormones or autocoids.
1 637 kr
Skickas inom 10-15 vardagar
Prostaglandins, Leukotrienes, and Cancer is a multi-volume series that will focus on an emerging area of cancer research. In 1968, R.H. Williams first reported that elevated prostaglandin levels are present in human medullary car- cinoma. Since that time, the concept that arachidonic acid metabolites may be in- volved in cancer has expanded to include every aspect of the disease from cell transformation through metastasis. Prostaglandins and leukotrienes are generic terms used to describe a family of bioactive lipids produced from unsaturated fatty acids (principally from and lipoxygenase pathways, respec- arachidonic acid) via the cyclooxygenase tively. Cyclooxygenase products consist of diverse products such as prosta- glandin E2 (POE), prostacyclin (POI) and thromboxane A2 (TXA), whereas 2 2 2 lipoxygenase products consist of hydroperoxy fatty acids and mono-, di- and tri-hydroxy acids including leukotrienes. The precursor fatty acids for the cyclooxygenase and lipoxygenase pathways are present in cellular phospholipids. This finding established an important control point in their biosynthesis-the release of substrate.This occurs in response to numerous stimuli that act at the cell surface. Dr. Bengt Samuelsson's extensive study of the metabolism of pros- taglandins indicated that they are rapidly inactivated on a single pass through pulmonary circulation. Thus, they cannot act as circulating hormones and appear to be made on demand in or in the vicinity of target tissues leading to the concept that prostaglandins are local hormones or autocoids.